KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Eli Lilly (LLY) Other Operating Expenses (2016 - 2019)

Eli Lilly filings provide 8 years of Other Operating Expenses readings, the most recent being -$151.7 million for Q4 2019.

  • On a quarterly basis, Other Operating Expenses rose 21.24% to -$151.7 million in Q4 2019 year-over-year; TTM through Sep 2020 was -$151.7 million, a 75.39% increase, with the full-year FY2019 number at -$9.1 billion, down 10.93% from a year prior.
  • Other Operating Expenses hit -$151.7 million in Q4 2019 for Eli Lilly, up from -$423.9 million in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $5.0 billion in Q4 2016 to a low of -$423.9 million in Q1 2019.
  • Median Other Operating Expenses over the past 5 years was -$57.4 million (2016), compared with a mean of $220.6 million.
  • Biggest five-year swings in Other Operating Expenses: soared 3526.71% in 2016 and later plummeted 793.41% in 2017.
  • Eli Lilly's Other Operating Expenses stood at -$144.9 million in 2015, then soared by 3526.71% to $5.0 billion in 2016, then tumbled by 100.89% to -$44.4 million in 2017, then tumbled by 333.78% to -$192.6 million in 2018, then increased by 21.24% to -$151.7 million in 2019.
  • The last three reported values for Other Operating Expenses were -$151.7 million (Q4 2019), -$423.9 million (Q1 2019), and -$192.6 million (Q4 2018) per Business Quant data.